XMD17-109 100 mg | Purity Not Available
TargetMol
XMD17-109 is a new selective ERK-5 inhibitor (EC50: 4.2 uM, HEK293 cells).
More Information Supplier PageXMD17-109
Search Results
XMD17-109 25 mg | Purity Not Available
TargetMol
XMD17-109 is a new selective ERK-5 inhibitor (EC50: 4.2 uM, HEK293 cells).
More Information Supplier PageXMD17-109
Reversine 2 mg | 98.00%
TargetMol
Reversine, a small synthetic purine analogue (2, 6-disubstituted purine), is a potent inhibitior of Aurora A/B/C(IC50s=150-500 nM).
More Information Supplier PageReversine
Dapivirine 2 mg | Purity Not Available
TargetMol
Dapivirine is a diarylpyrimidine non-nucleoside reverse transcriptase inhibitor.
More Information Supplier PageDapivirine
WH-4-023 25 mg | Purity Not Available
TargetMol
WH-4-023 is a potent and orally active Lck/Src inhibitor. It also potently inhibits SIK.
More Information Supplier PageWH-4-023
Kobe0065 100 mg | 100.00%
TargetMol
Kobe0065 is a novel and effective small-molecule compound inhibiting Ras–Raf interaction by SBDD; shows potent activity to competitively inhibit the binding of H-Ras·GTP to c-Raf-1 RBD with a Ki value of 46 ± 13 μM.
More Information Supplier PageKobe0065
Kobe0065 200 mg | 100.00%
TargetMol
Kobe0065 is a novel and effective small-molecule compound inhibiting Ras–Raf interaction by SBDD; shows potent activity to competitively inhibit the binding of H-Ras·GTP to c-Raf-1 RBD with a Ki value of 46 ± 13 μM.
More Information Supplier PageKobe0065
Des(benzylpyridyl) Atazanavi 100 mg | 98.00%
TargetMol
The N-dealkylated metabolite (M1) of Atazanavir, a HIV protease inhibitor.
More Information Supplier PageDes(benzylpyridyl) Atazanavi
3-AP 100 mg | 99.05%
TargetMol
3-AP (Triapine) is a novel inhibitor of the M2 subunit of ribonucleotide reductase (RR).
More Information Supplier Page3-AP
YL-109 25 mg | 98.00%
TargetMol
YL-109, a novel anticancer agent, can inhibit breast Y cell growth and invasiveness in vitro and in vivo.
More Information Supplier PageYL-109
